Key Drivers
- Liquidity Strength
- Margin Pressure
- Cash Flow Risk
AIAI Summary
PHAR has shifted from a “story stock” to a commercialization execution test: the Japan Joenja launch and pediatric expansion create real upside, but investors should focus on whether adoption can accelerate fast enough to offset RUCONEST decline, negative recent cash flow, and the 2026 revenue cut.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Strength
- •Margin Pressure
- •Cash Flow Risk
PHAR has a strong liquidity and gross-margin profile, but thin profitability, weak capital efficiency, recent cash-flow deterioration, and a rich valuation limit the upside.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Support holding
- •Overhead resistance
PHAR has rebounded above $11.72 and is holding the $10 support zone, but last month's downtrend is still intact and the stock remains a recovery move until it clears $12.35-$13.47.
Wide swing from $9.82 to $13.47 signals elevated volatility
Sentiment & News
Key News Insights:
- •Revenue miss
- •Guidance slashed
- •Japan launch
Pharming's weak Q2 results and sharply reduced 2026 outlook triggered a steep PHAR selloff and shareholder-law probes, even as Joenja expanded with a Japan launch. క క
The earnings miss and lower outlook are likely to keep PHAR under pressure, with Joenja's launch providing only partial offset
Similar Companies in Healthcare
Other companies in the same sector with AI ratings